Demographics and clinical features of the study population
| Characteristic | n=106 |
| Male, n (%) | 75 (70.8%) |
| Age, years (IQR) | 68 (58–74) |
| Ethnicity | |
| Non-Hispanic White | 102 (96.2%) |
| Hispanic | 2 (1.9%) |
| Black/African-American | 2 (1.9%) |
| Pre-admission ASA score | |
| 1 | 11 (10.4%) |
| 2 | 38 (35.8%) |
| 3 | 52 (49.1%) |
| 4 | 5 (4.7%) |
| Comorbidities | |
| Hypertension | 55/105 (52.4%) |
| Diabetes | 23/105 (21.9%) |
| Ischaemic cardiomyopathy | 17/105 (16.2%) |
| CKD | 15/105 (14.3%) |
| Obesity | 12/105 (11.4%) |
| COPD | 11/105 (10.5%) |
| Atrial fibrillation | 10/105 (9.5%) |
| Active cancer | 9/105 (8.6%) |
| Cirrhosis | 9/105 (8.6%) |
| Reason for admission | |
| COVID-19 related | 72 (67.9%) |
| Other (incidental SARS-CoV-2 diagnosis) | 34 (32.1%) |
| COVID respiratory disease | 86 (81.1%) |
| GI symptoms | n=90* |
| None | 50 (55.6%) |
| At least one symptom† | 40 (44.4%) |
| Abdominal pain | 25 (27.8%) |
| Nausea | 16 (17.8%) |
| Diarrhoea | 14 (15.6%) |
| Vomiting | 13 (14.4%) |
| Anorexia | 10 (11.1%) |
| Hospital regimen | |
| Intensive care unit, with invasive ventilation | 35 (33%) |
| Subintensive care | 71 (67%) |
| Relevant therapy during admission | |
| Antibiotics/antimicotic | 90/101 (89.1%) |
| Anticoagulation | 46/84 (54.8%) |
| Antivirals | 45/98 (45.9%) |
| Hydroxychloroquine | 41/99 (41.4%) |
| Biological therapy | 15/97 (15.5%) |
| Steroids | 28/100 (28%) |
*Excluding patients with symptoms related to other known abdominal diseases.
†More than one symptom admittible.
ASA, American Society of Anesthesiologists; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.